Physician profile
Roy D Barrow
NPI 1235135211
$1,545.49
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $219 · 2023: $13.10 · 2024: $38.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $195.29 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $193.82 | 2019-2020 | |
| Amgen INC. | $178.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $124.34 | 2019 | |
| Glaxosmithkline, LLC. | $110.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.90 | 2019 | |
| Arbor Pharmaceuticals, INC. | $63.86 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.10 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $61.69 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $51.14 | 2019 | |
| Grifols USA, LLC | $47.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.23 | 2019-2020 | |
| Amarin Pharma, INC. | $38.12 | 2019-2020 | |
| Boston Scientific Corporation | $37.88 | 2023-2024 | Wavewriter Alpha Prime 16, Resolution 360 Ultra Clip |
| Abbvie INC. | $30.44 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $28.73 | 2019 | |
| Pfizer INC. | $24.37 | 2019 | |
| Eisai INC. | $23.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.77 | 2019-2020 | |
| Aytu Biopharma, INC. | $20.67 | 2019 | |
| Mannkind Corporation | $18.45 | 2019 | |
| Genentech USA, INC. | $18.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.61 | 2019 | |
| Mylan Specialty L.P. | $14.40 | 2019 | |
| Allergan, INC. | $12.64 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.34 | 2019 | |
| Lilly USA, LLC | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Barrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.